Tigecycline to treatStenotrophomonas maltophiliaventilator‐associated pneumonia in a trauma intensive care unit as a result of a drug shortage: A case series

• DOI: 10.1111/jcpt.13158
• Publication Date: 2020-05-14T18:00:41Z
• Authors: Julie E. Farrar; Katelyn M. Garner; Joseph M. Swanson; Louis J. Magnotti; Martin A. Croce; G. Christopher Wood
• Keywords: Tigecycline; Stenotrophomonas maltophilia; Ventilator-associated Pneumonia; Economic shortage

What is known and objective Stenotrophomonas maltophilia an intrinsically multidrug-resistant (MDR) organism which commonly presents as a respiratory tract infection. S. typically treated with high-dose sulfamethoxazole/trimethoprim (SMX/TMP). However, SMX/TMP other treatment options for can be limited because of resistance, allergy, adverse events or unavailability the drug; use novel agents may necessary to adequately treat this MDR infection overcome these limitations. Case description This small case series describes two patients who underwent tigecycline ventilator-associated pneumonia (VAP) caused by after admission trauma intensive care unit. At time reported patients, national drug shortage intravenous (IV) prevented its use. Tigecycline was chosen agent VAP based on culture susceptibility data, it used successfully. Both showed clinical signs improvement eventual cure discharge from hospital tigecycline, one patient demonstrated confirmed microbiological negative repeat bronchoscopic bronchoalveolar lavage (BAL). new conclusion To our knowledge, first documentation utilizing in United States. Although likely should not considered first-line agent, proved effective option cases described setting choice.